Q-omics provides the consensus-scored AK4 profile across patient tissues and cancer cell-line models. AK4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, AK4 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, AK4 RNA expression shows 18,331 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KICH, and THYM as cancer lineages where AK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AK4 survival associations across molecular data types. AK4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AK4 RNA expression–survival associations across cancer types. High AK4 expression shows unfavorable associations in UVM, HNSC, LIHC, LUAD and STAD, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for AK4 RNA expression.
This table summarizes AK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AK4 shows lower tumor expression in KICH, KIRP, BLCA and BRCA and higher tumor expression in LUAD and LUSC. The KICH box plot shows higher AK4 RNA expression in normal versus tumor tissue (log2 FC = −4.798, t-test p < 0.001).
This table shows molecular features associated with AK4 in patient tissues and cancer cell lines. In patient samples, AK4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, AK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
